Having trouble accessing articles? Reset your cache.

Linaclotide: Phase III data

Top-line data from the double-blind, North American Phase III LIN-MD-31 trial in 803 patients showed that once-daily 266 µg oral linaclotide met all co-primary and secondary endpoints vs. placebo. In May, Ironwood said it planned to conduct separate analyses of its ongoing North American Phase III trials for the European Medicines Agency (EMA) and FDA using different primary endpoints. At that time, EMA indicated that it would allow the company to use its ongoing North American Phase

Read the full 775 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers